XBI vs. ARWR

Last updated Jun 5, 2026

XBI (SPDR S&P Biotech ETF) is Health & Biotech Equities fund tracking the S&P Biotechnology Select Industry Index, while ARWR (Arrowhead Pharmaceuticals, Inc.) is a stock. Over the past 10 years, XBI returned 8.53%/yr vs 28.26%/yr for ARWR. At a 0.47 correlation, their price movements are largely independent.

Performance

XBI vs. ARWR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in SPDR S&P Biotech ETF (XBI) and Arrowhead Pharmaceuticals, Inc. (ARWR). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, XBI achieves a 9.42% return, which is significantly lower than ARWR's 13.21% return. Over the past 10 years, XBI has underperformed ARWR with an annualized return of 8.53%, while ARWR has yielded a comparatively higher 28.26% annualized return.

XBI

• 1D: 2.77%
• 1M: -0.28%
• YTD: 9.42%
• 6M: 8.61%
• 1Y: 62.35%
• 3Y*: 15.65%
• 5Y*: 1.14%
• 10Y*: 8.53%

ARWR

• 1D: 3.60%
• 1M: 0.31%
• YTD: 13.21%
• 6M: 16.24%
• 1Y: 348.98%
• 3Y*: 29.01%
• 5Y*: -0.26%
• 10Y*: 28.26%

*Multi-year figures are annualized to reflect compound growth (CAGR)

XBI vs. ARWR - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
XBI SPDR S&P Biotech ETF	9.42%	35.89%	1.01%	7.60%	-25.87%	-20.45%	48.33%	32.56%	-15.28%	43.77%
ARWR Arrowhead Pharmaceuticals, Inc.	13.21%	253.14%	-38.56%	-24.56%	-38.82%	-13.59%	20.97%	410.71%	237.50%	137.42%

Correlation

The correlation between XBI and ARWR is 0.59, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.59
Correlation (3Y) Calculated over the trailing 3-year period	0.62
Correlation (5Y) Calculated over the trailing 5-year period	0.70
Correlation (10Y) Calculated over the trailing 10-year period	0.64
Correlation (All Time) Calculated using the full available price history since Feb 7, 2006	0.47

The correlation between XBI and ARWR shifts across timeframes, from 0.47 (all time) to 0.70 (5 years), reflecting how their relationship changes across market environments.

Return for Risk

XBI vs. ARWR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

XBI

XBI Risk / Return Rank: 80
XBI Sharpe Ratio Rank: 77
XBI Sortino Ratio Rank: 75
XBI Omega Ratio Rank: 67
XBI Calmar Ratio Rank: 93
XBI Martin Ratio Rank: 89

ARWR

ARWR Risk / Return Rank: 98
ARWR Sharpe Ratio Rank: 99
ARWR Sortino Ratio Rank: 97
ARWR Omega Ratio Rank: 96
ARWR Calmar Ratio Rank: 99
ARWR Martin Ratio Rank: 98

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

XBI vs. ARWR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for SPDR S&P Biotech ETF (XBI) and Arrowhead Pharmaceuticals, Inc. (ARWR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	XBI	ARWR	Difference
Sharpe ratio: Return per unit of total volatility	2.45	5.40	-2.95
Sortino ratio: Return per unit of downside risk	3.32	4.77	-1.45
Omega ratio: Gain probability vs. loss probability	1.40	1.60	-0.21
Calmar ratio: Return relative to maximum drawdown	6.45	14.27	-7.82
Martin ratio: Return relative to average drawdown	19.53	39.08	-19.55
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

XBI vs. ARWR - Sharpe Ratio Comparison

The current XBI Sharpe Ratio is 2.45, which is lower than the ARWR Sharpe Ratio of 5.40. The chart below compares the historical Sharpe Ratios of XBI and ARWR, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	XBI	ARWR	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.45	5.40	-2.95
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.04	-0.00	+0.04
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.27	0.38	-0.11
Sharpe Ratio (All Time) Calculated using the full available price history	0.36	-0.01	+0.37

Drawdowns

XBI vs. ARWR - Drawdown Comparison

The maximum XBI drawdown since its inception was -63.89%, smaller than the maximum ARWR drawdown of -99.24%. Use the drawdown chart below to compare losses from any high point for XBI and ARWR.

Drawdown Indicators

	XBI	ARWR	Difference
Max Drawdown Largest peak-to-trough decline	-63.89%	-99.24%	+35.35%
Max Drawdown (1Y) Largest decline over 1 year	-9.72%	-24.64%	+14.92%
Max Drawdown (3Y) Largest decline over 3 years	-32.99%	-74.70%	+41.71%
Max Drawdown (5Y) Largest decline over 5 years	-54.71%	-88.94%	+34.23%
Max Drawdown (10Y) Largest decline over 10 years	-63.89%	-88.96%	+25.07%
Current Drawdown Current decline from peak	-22.89%	-53.75%	+30.86%
Average Drawdown Average peak-to-trough decline	-20.93%	-81.24%	+60.31%
Ulcer Index Depth and duration of drawdowns from previous peaks	3.20%	8.98%	-5.78%

Volatility

XBI vs. ARWR - Volatility Comparison

The current volatility for SPDR S&P Biotech ETF (XBI) is 9.69%, while Arrowhead Pharmaceuticals, Inc. (ARWR) has a volatility of 17.48%. This indicates that XBI experiences smaller price fluctuations and is considered to be less risky than ARWR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	XBI	ARWR	Difference
Volatility (1M) Calculated over the trailing 1-month period	9.69%	17.48%	-7.79%
Volatility (6M) Calculated over the trailing 6-month period	20.31%	39.45%	-19.14%
Volatility (1Y) Calculated over the trailing 1-year period	25.60%	65.09%	-39.49%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	32.20%	65.01%	-32.81%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	32.00%	74.14%	-42.14%

Dividends

XBI vs. ARWR - Dividend Comparison

XBI's dividend yield for the trailing twelve months is around 0.33%, while ARWR has not paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
ARWR Arrowhead Pharmaceuticals, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
XBI SPDR S&P Biotech ETF	0.33%	0.37%	0.15%	0.02%	0.00%	0.04%	0.20%	0.00%	0.28%	0.24%	0.26%	0.61%

Frequently Asked Questions

Can I hold both XBI and ARWR in my portfolio?

XBI and ARWR have a correlation of 0.59, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, XBI or ARWR?

ARWR has higher volatility (17.48%) compared to XBI (9.69%). In terms of maximum drawdown, XBI dropped -63.89% vs ARWR's -99.24%.

Which has better risk-adjusted returns?

ARWR currently has the higher Sharpe Ratio (5.40 vs 2.45), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.